Improving CAR-T Immunotherapy for Lymphoma by fine-tuning avidity

Duration

30 min

Collaborators

Prof. Marco Ruella, MD Associate Professor of Medicine and Director of Lymphoma Program, University of Pennsylvania

Commercial CAR-T therapies still suffer from severe limitations, as majority of patients fail to achieve complete response and ultimately relapse.

Watch this Webinar to discover Prof. Marco Ruella’s team have adopted a novel CAR-T avidity screening method to improve safety and exhaustion profile, leading to 100% clinical response in a phase I trial.

Learning objectives:

Explore the groundbreaking approach of selecting the right CAR for cell therapy application. Learn how an innovative CAR binder leads to enhanced clinical response compared to currently available commercial CAR. What makes this different from conventional CAR T cell therapies?
Discover how tuning the fine balance between T cell engagement and exhaustion in CAR T cells leads to a more durable anti-tumor response and superior clinical outcome.
Uncover the innovative strategy used to reduce Activation-Induced Cell Death (AICD) in CAR T cells, a key challenge in providing durable and complete response for patients.